Rolf Mahlberg

6.1k total citations
30 papers, 1.0k citations indexed

About

Rolf Mahlberg is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Rolf Mahlberg has authored 30 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 9 papers in Surgery. Recurrent topics in Rolf Mahlberg's work include Gastric Cancer Management and Outcomes (13 papers), Esophageal Cancer Research and Treatment (8 papers) and Colorectal Cancer Treatments and Studies (5 papers). Rolf Mahlberg is often cited by papers focused on Gastric Cancer Management and Outcomes (13 papers), Esophageal Cancer Research and Treatment (8 papers) and Colorectal Cancer Treatments and Studies (5 papers). Rolf Mahlberg collaborates with scholars based in Germany, France and Austria. Rolf Mahlberg's co-authors include Ralf‐Dieter Hofheinz, Nils Homann, Claudia Pauligk, Volker Rethwisch, Elke Jäger, Stephan Probst, Oliver A. Cornely, Helmut Ostermann, G. Seipelt and Xaver Schiel and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Rolf Mahlberg

24 papers receiving 999 citations

Peers

Rolf Mahlberg
Comparison fields: 5 of 65
  • Oncology 510
  • Pulmonary and Respiratory Medicine 388
  • Surgery 226
  • Hematology 220
  • Public Health, Environmental and Occupational Health 181
Replace Munita Bal with:
Munita Bal India
Andreas Prachalias United Kingdom
C D Gerharz Germany
José M. Enríquez–Navascués Spain
Jonathan Cotliar United States
Carmel Stock United Kingdom
Morel Rubinger Canada
Marcia K. Liepman United States
Lucie Planche France
Mauricette Michallet France
Munita Bal India View profile →
Citations per field, relative to Rolf Mahlberg
Rolf Mahlberg · 1×
Citations per year, relative to Rolf Mahlberg
Rolf Mahlberg · 1×

Countries citing papers authored by Rolf Mahlberg

Since Specialization
Citations

This map shows the geographic impact of Rolf Mahlberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rolf Mahlberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rolf Mahlberg more than expected).

Fields of papers citing papers by Rolf Mahlberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rolf Mahlberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rolf Mahlberg. The network helps show where Rolf Mahlberg may publish in the future.

Co-authorship network of co-authors of Rolf Mahlberg

This figure shows the co-authorship network connecting the top 25 collaborators of Rolf Mahlberg. A scholar is included among the top collaborators of Rolf Mahlberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rolf Mahlberg. Rolf Mahlberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial
2024 ·Oncology Research and Treatment ·(unknown), Thorsten Oliver Goetze, Thomas J. Ettrich, Harald Schmalenberg, Michael Clemens, Rolf Mahlberg, Steffen Heeg, Stephan Kanzler, (unknown), Peter Thuss-Patience, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Claudia Pauligk, Salah‐Eddin Al‐Batran, Sylvie Lorenzen
0
2
S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma–final results of the randomized AIO MATEO phase II trial
2023 ·ESMO Open ·(unknown), Sylvie Lorenzen, Thomas J. Ettrich, (unknown), Federico Longo, Alexander Kiani, Marino Venerito, Jörg Trojan, Rolf Mahlberg, Nicolas Moosmann, Benoist Chibaudel, Stefan Kubicka, Richard Greil, S Daum, Michael Geißler, Julian Larcher‐Senn, Gisela Keller, Florian Lordick, Georg Martin Haag
1
3
86P Patients (pts) preference for different administration methods of trastuzumab (T) in pts with HER2+ early breast cancer (BC) treated within the GAIN-2 trial
2020 ·Annals of Oncology ·Mattea Reinisch, Michael Untch, Toralf Reimer, Rolf Mahlberg, Mustafa Aydoğdu, T Hitschold, Christian Jackisch, Frederik Marmé, (unknown), (unknown), Sabine Schmatloch, Marcus Schmidt, Peter Klare, Bruno V. Sinn, Elmar Stickeler, Sabine Seiler, Julia Rey, (unknown), Volker Möbus, Sibylle Loibl
1
4
1447P S-1 maintenance therapy in non-Asian patients with advanced, Her-2 negative esophagogastric adenocarcinoma – First results of the international MATEO trial initiated by the AIO
2020 ·Annals of Oncology ·Georg Martin Haag, (unknown), Sylvie Lorenzen, Thomas J. Ettrich, Federico Longo, Alexander Kiani, Marino Venerito, Jörg Trojan, Rolf Mahlberg, Nicolas Moosmann, Benoist Chibaudel, Stefan Kubicka, Richard Greil, S Daum, Michael Geißler, (unknown), Florian Lordick
2
5
1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma
2020 ·Annals of Oncology ·S-E. Al-Batran, (unknown), Thomas J. Ettrich, K Borchert, A. Kretzschmar, Christian Teschendorf, Gabriele Margareta Siegler, (unknown), Eray Goekkurt, Manfred Welslau, Rolf Mahlberg, Nils Homann, Daniel Pink, Wolf O. Bechstein, Peter Reichardt, Timo Gaiser, Disorn Sookthai, Claudia Pauligk, Thorsten Oliver Goetze, Ralf‐Dieter Hofheinz
15
6
1502TiP Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs - RAMOS, a randomized phase II trial of the German Gastric Group of the AIO
2020 ·Annals of Oncology ·Sylvie Lorenzen, Claudia Pauligk, (unknown), (unknown), Rolf Mahlberg, Harald Schmalenberg, Alexander Biederstädt, (unknown), (unknown), (unknown), (unknown), Ralf‐Dieter Hofheinz, Markus Moehler, S-E. Al-Batran
0
7
Abstract P5-20-09: Pharmacokinetic results of a subcutaneous injection of trastuzumab into the thigh versus into the abdominal wall in patients with HER2-positive primary breast cancer (BC) treated within the neo-/adjuvant GAIN-2 study
2018 ·Cancer Research ·Volker Möbus, Rolf Mahlberg, Wolfgang Janni, (unknown), Frederik Marmé, Helmut Forstbauer, Toralf Reimer, Albert von der Assen, Mattea Reinisch, Ralf Lorenz, Sabine Schmatloch, (unknown), (unknown), (unknown), Elmar Stickeler, Michael Untch, Sabine Seiler, Nicole Burchardi, Gϋnter von Minckwitz, Sibylle Loibl
0
8
Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
2017 ·Annals of Hematology ·Werner Heinz, Dieter Buchheidt, Maximilian Christopeit, Marie von Lilienfeld‐Toal, Oliver A. Cornely, Hermann Einsele, Meinolf Karthaus, Hartmut Link, Rolf Mahlberg, Silke Neumann, Helmut Ostermann, Olaf Penack, Markus Ruhnke, Michael Sandherr, Xaver Schiel, Jörg Janne Vehreschild, Florian Weißinger, Georg Maschmeyer
100
9
New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin
2016 ·Chemotherapy ·Rolf Mahlberg, Sylvie Lorenzen, Peter Thuss‐Patience, Volker Heinemann, Per Pfeiffer, Markus Möhler
34
10
Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer
2016 ·Gastric Cancer ·Markus Moehler, Rolf Mahlberg, Volker Heinemann, Radka Obermannová, Eugen Kubala, Bohuslav Melichar, Arndt Weinmann, P. Scigalla, (unknown), (unknown), (unknown), Wasat Mansoor
4
11
Optimization of Rituximab for Treatment of DLBCL in Young, High-Risk Patients-Results of the Dense-R-CHOEP Trial of the German High-Grade Lymphoma Study Group
2015 ·Blood ·Norbert Schmitz, Maike Nickelsen, Marita Ziepert, Mathias Haenel, Andreas Viardot, Martin Dreyling, Peter Borchmann, Carsten Bokemeyer, Christian Peschel, Hans‐Heinrich Wolf, Rolf Mahlberg, Michael Pfreundschuh, Bertram Glaß
2
12
The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas
2014 ·Blood ·Niels Murawski, Gerhard Held, Marita Ziepert, B. Kempf, Andreas Viardot, Mathias Hänel, Mathias Witzens‐Harig, Rolf Mahlberg, Christian Rübe, Jochen Fleckenstein, Carsten Zwick, Bertram Glaß, Norbert Schmitz, Samira Zeynalova, Michael Pfreundschuh
31
13
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)
2012 ·European Journal of Cancer ·Salah‐Eddin Al‐Batran, Claudia Pauligk, Nils Homann, Jörg T. Hartmann, Markus Moehler, Stephan Probst, Volker Rethwisch, Jan Stoehlmacher-Williams, Nicole Prasnikar, Stephan Hollerbach, Carsten Bokemeyer, Rolf Mahlberg, Ralf‐Dieter Hofheinz, Kim Barbara Luley, Frank Kullmann, Elke Jäger
102
14
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
2008 ·Annals of Oncology ·S. Al-Batran, J. T. Hartmann, Ralf‐Dieter Hofheinz, Nils Homann, Volker Rethwisch, Stephan Probst, Jan Stoehlmacher, Michael Clemens, Rolf Mahlberg, Mary Ann Fritz, G. Seipelt, Mark Sievert, Claudia Pauligk, Akin Atmaca, Elke Jäger
183
15
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer
2007 ·Annals of Oncology ·Stefan Boeck, Thomas Hoehler, G. Seipelt, Rolf Mahlberg, A. Wein, Andreas Hochhaus, (unknown), Bernd Schmid, E. Kettner, Martina Stauch, Florian Lordick, Y. Ko, Michael Geißler, (unknown), G. Kojouharoff, Alexander Golf, (unknown), Volker Heinemann
59
16
Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase 2 trial
2007 ·Critical Reviews in Oncology/Hematology ·Gilles Romieu, Michael Clemens, Rolf Mahlberg, P. Fargeot, Manuel Constenla, (unknown), (unknown), Tomáš Skácel, P. Bacon, Wolfram Brugger
33
17
Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia
2006 ·Leukemia ·Uwe Platzbecker, Christian Thiede, Monika Füssel, G Geissler, Thomas Illmer, Brigitte Mohr, Mathias Hänel, Rolf Mahlberg, (unknown), Florian Weißinger, Markus Schaich, Catrin Theuser, Gerhard Ehninger, Martin Bornhäuser
45
18
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
2005 ·Blood ·Barbara Waßmann, Roman Pfeifer, Michael Stadler, Martin Bornhäuser, Gesine Bug, Urban Scheuring, Patrick T. Bruck, Matthias Stelljes, Rainer Schwerdtfeger, Nadežda Basara, Jolanta B. Perz, Donald Bunjes, Georg Ledderose, Rolf Mahlberg, Anja Binckebanck, Harald Gschaidmeier, Dieter Hoelzer, Oliver G. Ottmann
149
19
Hämatologie
2004 ·Rolf Mahlberg, (unknown), (unknown)
0
20
The valency state of absorbed iron appearing in the portal blood and ceruloplasmin substitution
1990 ·BioMetals ·Peter Wollenberg, Rolf Mahlberg, W. Rummel
17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Munita Bal Breakdown of academic impact, for papers by Andreas Prachalias Breakdown of academic impact, for papers by C D Gerharz Breakdown of academic impact, for papers by José M. Enríquez–Navascués Breakdown of academic impact, for papers by Jonathan Cotliar Breakdown of academic impact, for papers by Carmel Stock Breakdown of academic impact, for papers by Morel Rubinger Breakdown of academic impact, for papers by Marcia K. Liepman Breakdown of academic impact, for papers by Lucie Planche Breakdown of academic impact, for papers by Mauricette Michallet
Rankless by CCL
2026